Latest Insider Transactions at Kronos Bio, Inc. (KRON)
This section provides a real-time view of insider transactions for Kronos Bio, Inc. (KRON). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kronos Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kronos Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2021
|
Marianne De Backer Director |
BUY
Open market or private purchase
|
Direct |
1,150
+29.49%
|
$12,650
$11.57 P/Share
|
|
Oct 04
2021
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,189
-8.71%
|
$183,780
$20.81 P/Share
|
|
Oct 04
2021
|
Christopher Dinsmore Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,189
+8.01%
|
$27,567
$3.27 P/Share
|
|
Sep 07
2021
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,189
-8.71%
|
$192,969
$21.91 P/Share
|
|
Sep 07
2021
|
Christopher Dinsmore Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,189
+8.01%
|
$27,567
$3.27 P/Share
|
|
Aug 20
2021
|
Marianne De Backer Director |
BUY
Open market or private purchase
|
Direct |
1,000
+27.53%
|
$19,000
$19.57 P/Share
|
|
Aug 02
2021
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,189
-8.71%
|
$183,780
$20.59 P/Share
|
|
Aug 02
2021
|
Christopher Dinsmore Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,189
+8.01%
|
$27,567
$3.27 P/Share
|
|
May 28
2021
|
Marianne De Backer Director |
BUY
Open market or private purchase
|
Direct |
600
+50.0%
|
$15,000
$25.01 P/Share
|
|
Apr 20
2021
|
Jakob Loven Director |
SELL
Open market or private sale
|
Indirect |
21,551
-0.81%
|
$431,020
$20.37 P/Share
|
|
Apr 19
2021
|
Jakob Loven Director |
SELL
Open market or private sale
|
Indirect |
14,004
-0.52%
|
$280,080
$20.82 P/Share
|
|
Apr 16
2021
|
Jakob Loven Director |
SELL
Open market or private sale
|
Indirect |
33,162
-1.22%
|
$696,402
$21.2 P/Share
|
|
Apr 15
2021
|
Jakob Loven Director |
SELL
Open market or private sale
|
Indirect |
24,818
-1.78%
|
$521,178
$21.78 P/Share
|
|
Apr 14
2021
|
Jakob Loven Director |
SELL
Open market or private sale
|
Indirect |
32,636
-1.15%
|
$717,992
$22.74 P/Share
|
|
Apr 13
2021
|
Jakob Loven Director |
SELL
Open market or private sale
|
Indirect |
17,020
-0.39%
|
$408,480
$24.31 P/Share
|
|
Apr 12
2021
|
Jakob Loven Director |
SELL
Open market or private sale
|
Indirect |
15,828
-0.54%
|
$411,528
$26.74 P/Share
|
|
Apr 09
2021
|
Jakob Loven Director |
SELL
Open market or private sale
|
Indirect |
21,660
-1.46%
|
$584,820
$27.2 P/Share
|
|
Apr 08
2021
|
Jakob Loven Director |
SELL
Open market or private sale
|
Indirect |
63,128
-2.06%
|
$1,704,456
$27.5 P/Share
|
|
Dec 10
2020
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
198,124
+50.0%
|
-
|
|
Dec 09
2020
|
Yasir B. Al Wakeel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,422
+39.78%
|
-
|
|
Dec 09
2020
|
Jorge Di Martino Chief Medical Officer & VP |
BUY
Grant, award, or other acquisition
|
Direct |
133,937
+50.0%
|
-
|
|
Dec 09
2020
|
Christopher Dinsmore Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
91,110
+48.6%
|
-
|
|
Dec 09
2020
|
Barbara Kosacz COO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
69,824
+9.26%
|
-
|
|
Oct 14
2020
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Conversion of derivative security
|
Indirect |
3,208,835
+34.92%
|
$51,341,360
$16.15 P/Share
|
|
Oct 14
2020
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
95,500
+2.14%
|
$1,814,500
$19.0 P/Share
|
|
Oct 14
2020
|
Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
95,500
+2.14%
|
$1,814,500
$19.0 P/Share
|
|
Oct 14
2020
|
Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,153,835
+14.81%
|
$34,461,360
$16.15 P/Share
|
|
Oct 14
2020
|
Yasir B. Al Wakeel Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,250
+12.36%
|
$99,750
$19.0 P/Share
|
|
Oct 14
2020
|
Christopher Dinsmore Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
5,250
+50.0%
|
$99,750
$19.0 P/Share
|
|
Oct 14
2020
|
Barbara Kosacz COO & General Counsel |
BUY
Open market or private purchase
|
Direct |
5,250
+0.85%
|
$99,750
$19.0 P/Share
|
|
Oct 14
2020
|
Arie Belldegrun |
BUY
Conversion of derivative security
|
Indirect |
2,739,052
+31.1%
|
$43,824,832
$16.15 P/Share
|
|
Oct 14
2020
|
Rebecka Belldegrun Director |
BUY
Conversion of derivative security
|
Indirect |
423,738
+27.79%
|
-
|
|
Oct 14
2020
|
Joshua A Kazam |
BUY
Conversion of derivative security
|
Direct |
92,371
+45.0%
|
-
|
|
Oct 14
2020
|
Jakob Loven Director |
BUY
Conversion of derivative security
|
Indirect |
1,545,344
+29.93%
|
$24,725,504
$16.15 P/Share
|
|
Oct 14
2020
|
John C Martin Director |
BUY
Open market or private purchase
|
Indirect |
75,800
+3.74%
|
$1,440,200
$19.0 P/Share
|
|
Oct 14
2020
|
John C Martin Director |
BUY
Conversion of derivative security
|
Indirect |
1,876,564
+30.34%
|
$30,025,024
$16.15 P/Share
|
|
Oct 14
2020
|
Elena Ridloff |
BUY
Open market or private purchase
|
Direct |
2,630
+50.0%
|
$49,970
$19.0 P/Share
|
|
Oct 14
2020
|
David M Tanen |
BUY
Conversion of derivative security
|
Indirect |
339,355
+19.99%
|
$5,429,680
$16.15 P/Share
|
|
Oct 14
2020
|
David M Tanen |
BUY
Conversion of derivative security
|
Direct |
231,553
+38.92%
|
-
|
|
Oct 14
2020
|
Otello Stampacchia Director |
BUY
Open market or private purchase
|
Indirect |
450,000
+10.54%
|
$8,550,000
$19.0 P/Share
|
|
Oct 14
2020
|
Otello Stampacchia Director |
BUY
Conversion of derivative security
|
Indirect |
3,348,832
+30.31%
|
$53,581,312
$16.15 P/Share
|
|
Oct 14
2020
|
Omega Fund V, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
450,000
+10.54%
|
$8,550,000
$19.0 P/Share
|
|
Oct 14
2020
|
Omega Fund V, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,348,832
+30.31%
|
$53,581,312
$16.15 P/Share
|